Changes in serum zinc levels in hepatitis C patients before and after treatment with direct-acting antiviral agents
| Autor: | Naohiko Tokutomi, Osamu Okawa, Masaya Tamano, Toshikuni Suda, Ryosaku Shirahashi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Elbasvir Hepatology biology business.industry Hepatitis C virus Serum albumin Hepatitis C Glecaprevir medicine.disease_cause medicine.disease Gastroenterology Pibrentasvir 03 medical and health sciences 0302 clinical medicine Infectious Diseases Grazoprevir 030220 oncology & carcinogenesis Internal medicine medicine Zinc deficiency biology.protein 030211 gastroenterology & hepatology business |
| Zdroj: | Hepatology research : the official journal of the Japan Society of HepatologyReferences. 49(11) |
| ISSN: | 1386-6346 |
| Popis: | AIM Zinc supplementation therapy has been shown to improve the prognosis of patients with hepatitis C virus (HCV) infection. However, little is known about the changes in serum zinc levels with treatment using direct-acting antiviral agents (DAAs). This prospective study investigated the changes in serum zinc levels before and after treatment with DAAs in hepatitis C patients. METHODS Thirty-one patients with chronic hepatitis C or HCV-related compensated cirrhosis who were treated with DAAs (glecaprevir/pibrentasvir or elbasvir/grazoprevir) were included in the study. Serum zinc and serum albumin levels were measured before DAA treatment (Baseline), at the end of treatment (EOT), and at 12 weeks after EOT (Follow-up 12). The changes over time in the serum zinc and serum albumin levels were investigated. RESULTS The mean age of the patients was 68.5 ± 12.1 (range, 40-86) years, and 17 (55%) were women. Based on the Japanese Society of Clinical Nutrition diagnostic criteria, 6 patients had zinc deficiency ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |